close

Enter

Log in using OpenID

Duchenne Duchenne Muscular Dystrophy Treatment Market will Exceed US$ 10,664.5 million by 2026 Treatment Market

embed
Duchenne Muscular Dystrophy Treatment Market will Exceed US$ 10,664.5 million by 2026
Duchenne Muscular Dystrophy Treatment Market to Reach US$ 10,664.5 million by 2026
As per the report by Persistence Market Research (PMR), the global duchenne muscular dystrophy
market is expected to experience strong growth. The market is also estimated to expand at a CAGR
of 48.3% during the forecast period. The global duchenne muscular dystrophy market is estimated
to bring in US$ 10,664.5 million revenue by the end of 2026.
Duchenne Muscular Dystrophy (DMD) is a type of muscular disorder due to which most of the
people are unable to walk at a very early stage and the affected muscles look larger due to the fat
content. The symptoms include muscle weakness, difficulty in walking and breathing and
intellectual disability. Although, the treatment to control and reduce the signs and symptoms is
available, yet there is no cure for DMD. Key players in the market are also trying to spread
awareness about DMD along with the investment in finding a treatment for the disease. Meanwhile,
human clinical trials are also underway to find out effective therapy.
Duchenne Muscular Dystrophy Treatment Market Research Report Overview @
https://www.persistencemarketresearch.com/market-research/duchenne-muscular-dystrophytreatment-market.asp
Various pharmaceutical companies and organizations are increasingly investing in the research and
development activities to come up with an effective treatment for duchenne muscular dystrophy.
Meanwhile, there is an ongoing research on gene therapy, exon skipping drugs, and stem cell
therapy to treat duchenne muscular dystrophy in a better way. Current pharmacological
interventions for duchenne muscular dystrophy include approaches to mitigate downstream and
secondary pathological mechanisms and solutions targeting primary defect. Patients with DMD are
not able to produce a protein known as dystrophin. Hence, a variety of new medications are being
developed to replace dystrophin. Moreover, new therapies aim to repair muscle damage caused due
to the absence of dystrophin. However, delay in diagnosis and the high cost of treatment and drugs
are some of the factors restricting the growth of the market.
The global duchenne muscular dystrophy market is segmented into therapy, distribution channel,
product type, and region. The product type is further segmented into corticosteroids, NSAIDs, and
other products. Among these, corticosteroids are likely to witness the highest growth during the
forecast period. By the end of 2026, corticosteroids are estimated to bring in more than US$ 9,000
million revenue. Based on the distribution channel, the global duchenne muscular dystrophy market
segmentation includes online pharmacies, retail pharmacies, and hospital pharmacies. Hospitals
pharmacies are expected to be the largest distributors in the duchenne muscular dystrophy market.
Hospital pharmacies are anticipated to exceed US$ 6,000 million revenue towards the end of 2026.
Request Sample [email protected] https://www.persistencemarketresearch.com/samples/12475
On the basis of therapy, the market segmentation includes Exon Skipping Approach, Mutation
Suppression, and other therapies. Mutation suppression therapy is expected to witness strong
growth throughout the forecast period. By the end of 2026, mutation suppression therapy is
estimated to bring in more than US$ 6,400 million revenue.
Europe is expected to be the dominating region in the global duchenne muscular dystrophy market
during the forecast period. Owing to the high rate of people suffering from duchenne muscular
dystrophy, Europe is witnessing the growth in adoption of treatment for muscular dystrophy. Also,
various treatments are approved or under review to treat duchenne muscular dystrophy in Europe.
This is also one of the reasons for the growth of the market in Europe.
Sarepta Therapeutics, Inc., Santhera Pharmaceuticals, PTC Therapeutics, Summit Therapeutics plc,
FibroGen, Inc., and ITALFARMACO S.p.A., are some of the leading players in the global
duchenne muscular dystrophy market.
Author
vakhas
vakhas298   documents Email
Document
Category
Uncategorized
Views
6
File Size
34 KB
Tags
treatment
1/--pages
Report inappropriate content